SELLAS Life Sciences Group, Inc. Preferred Stock Dividends, Income Statement Impact
SELLAS Life Sciences Group, Inc. (SLS) reported Preferred Stock Dividends, Income Statement Impact of $0 for the 12-month period ending 2019-12-31, per its 10-K filed 2020-03-13.
Discontinued › Expense Statement › Operating Expenses
us-gaap:PreferredStockDividendsIncomeStatementImpact · last filed 2020-03-13
- SELLAS Life Sciences Group, Inc. preferred stock dividends, income statement impact for the quarter ending 2019-12-31 was $0.00.
- SELLAS Life Sciences Group, Inc. preferred stock dividends, income statement impact for the quarter ending 2019-09-30 was $0.00.
- SELLAS Life Sciences Group, Inc. preferred stock dividends, income statement impact for the quarter ending 2019-06-30 was $0.00, a 100.00% decline year-over-year.
- SELLAS Life Sciences Group, Inc. preferred stock dividends, income statement impact for the quarter ending 2019-03-31 was $0.00, a 100.00% decline year-over-year.
- SELLAS Life Sciences Group, Inc. preferred stock dividends, income statement impact for fiscal 2019 was $0.00, a 100.00% decline from fiscal 2018.
- SELLAS Life Sciences Group, Inc. preferred stock dividends, income statement impact for fiscal 2018 was $4.44M.
- SELLAS Life Sciences Group, Inc. preferred stock dividends, income statement impact for fiscal 2017 was $0.00.
| Period end | Preferred Stock Dividends, Income Statement Impact 3 month | Preferred Stock Dividends, Income Statement Impact 6 month | Preferred Stock Dividends, Income Statement Impact 9 month | Preferred Stock Dividends, Income Statement Impact 12 month |
|---|---|---|---|---|
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-13 | $0.00 derived: sum of 2 quarters · filed 2020-03-13 | $0.00 derived: sum of 3 quarters · filed 2020-03-13 | $0.00 10-K · filed 2020-03-13 |
| 2019-09-30 | $0.00 10-Q · filed 2019-11-14 | $0.00 derived: sum of 2 quarters · filed 2019-11-14 | $0.00 10-Q · filed 2019-11-14 | $0.00 derived: sum of 4 quarters · filed 2020-03-13 |
| 2019-06-30 | $0.00 10-Q · filed 2019-08-14 | $0.00 10-Q · filed 2019-08-14 | $0.00 derived: sum of 3 quarters · filed 2020-03-13 | $0.00 derived: sum of 4 quarters · filed 2020-03-13 |
| 2019-03-31 | $0.00 10-Q · filed 2019-05-15 | $0.00 derived: sum of 2 quarters · filed 2020-03-13 | $0.00 derived: sum of 3 quarters · filed 2020-03-13 | $2.47M derived: sum of 4 quarters · filed 2020-03-13 |
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-13 | $0.00 derived: sum of 2 quarters · filed 2020-03-13 | $2.47M derived: sum of 3 quarters · filed 2020-03-13 | $4.44M 10-K · filed 2020-03-13 |
| 2018-09-30 | $0.00 10-Q · filed 2019-11-14 | $2.47M derived: sum of 2 quarters · filed 2019-11-14 | $4.44M 10-Q · filed 2019-11-14 | $4.44M derived: sum of 4 quarters · filed 2019-11-14 |
| 2018-06-30 | $2.47M 10-Q · filed 2019-08-14 | $4.44M 10-Q · filed 2019-08-14 | $4.44M derived: sum of 3 quarters · filed 2019-08-14 | $4.44M derived: sum of 4 quarters · filed 2019-08-14 |
| 2018-03-31 | $1.97M 10-Q · filed 2019-05-15 | $1.97M derived: sum of 2 quarters · filed 2019-05-15 | $1.97M derived: sum of 3 quarters · filed 2019-05-15 | $1.97M derived: sum of 4 quarters · filed 2019-05-15 |
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-22 | $0.00 derived: sum of 2 quarters · filed 2019-03-22 | $0.00 derived: sum of 3 quarters · filed 2019-03-22 | $0.00 10-K · filed 2019-03-22 |
| 2017-09-30 | $0.00 10-Q · filed 2018-11-14 | $0.00 derived: sum of 2 quarters · filed 2018-11-14 | $0.00 10-Q · filed 2018-11-14 | |
| 2017-06-30 | $0.00 10-Q · filed 2018-08-14 | $0.00 10-Q · filed 2018-08-14 | ||
| 2017-03-31 | $0.00 10-Q · filed 2018-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |